Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Launched by METHODIST HEALTH SYSTEM · Jan 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different medications used in combination with aspirin, called clopidogrel and ticagrelor, in patients who have a low platelet count (a condition known as thrombocytopenia) and need a procedure called Percutaneous Coronary Intervention (PCI). The research aims to find out if using clopidogrel results in fewer bleeding problems compared to ticagrelor in these patients after they receive either a Drug Eluting Stent (DES) or a Bare Metal Stent (BMS).

To be eligible for this trial, participants must be at least 18 years old and have had a PCI procedure during the study period, with a documented low platelet count at least once before the procedure. They will need to take both aspirin and one of the study medications after the procedure. Throughout the trial, participants will be closely monitored for any bleeding complications. It’s important to note that those who have died within 48 hours after the procedure or who received DAPT before the cardiac procedure cannot participate. If you or a loved one meet these criteria and are interested, this trial could help improve treatment options for patients with low platelet counts undergoing heart procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 18 years
• • PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
• • Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
• • At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
• Exclusion Criteria:
• • Death within 48 hours post-PCI
• • DAPT prior to cardiac catheterization